Published by: Kowsar

HER4 rs1595065 3'UTR Variant is a Possible Risk Factor for HER2 Positivity Among Breast Cancer Patients

Bahareh Moradi 1 , Hossein Tabatabaeian 2 , Samira Sadeghi 2 , Mansoureh Azadeh 1 and Kamran Ghaedi 3 , *
Authors Information
1 Najafabad Branch, Islamic Azad University, Najafabad, Isfahan, Iran
2 Genetics Division, Biology Department, Faculty of Sciences, University of Isfahan, Isfahan, Iran
3 Cellular and Molecular Biology Division, Biology Department, Faculty of Sciences, University of Isfahan, Isfahan, Iran
Article information
  • Thrita: December 2016, 5 (4); e42195
  • Published Online: November 19, 2016
  • Article Type: Research Article
  • Received: September 11, 2016
  • Revised: November 8, 2016
  • Accepted: November 10, 2016
  • DOI: 10.5812/thrita.42195

To Cite: Moradi B, Tabatabaeian H, Sadeghi S, Azadeh M, Ghaedi K. et al. HER4 rs1595065 3'UTR Variant is a Possible Risk Factor for HER2 Positivity Among Breast Cancer Patients, Thrita. 2016 ;5(4):e42195. doi: 10.5812/thrita.42195.

Copyright © 2016, Thrita. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1): 5-29[DOI][PubMed]
  • 2. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007; 447: 1087-93[DOI]
  • 3. Allman R, Dite GS, Hopper JL, Gordon O, Starlard-Davenport A, Chlebowski R, et al. SNPs and breast cancer risk prediction for African American and Hispanic women. Breast Cancer Res Treat. 2015; 154(3): 583-9[DOI][PubMed]
  • 4. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009; 21(2): 177-84[DOI][PubMed]
  • 5. Fujiwara S, Ibusuki M, Yamamoto S, Yamamoto Y, Iwase H. Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis. Breast Cancer. 2014; 21(4): 472-81[DOI][PubMed]
  • 6. Bacus SS, Chin D, Yarden Y, Zelnick CR, Stern DF. Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. Am J Pathol. 1996; 148(2): 549-58[PubMed]
  • 7. Kew TY, Bell JA, Pinder SE, Denley H, Srinivasan R, Gullick WJ, et al. c-erbB-4 protein expression in human breast cancer. Br J Cancer. 2000; 82(6): 1163-70[DOI][PubMed]
  • 8. Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, Schwarz S, et al. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res. 2008; 10(1): 2[DOI][PubMed]
  • 9. Koutras AK, Kalogeras KT, Dimopoulos MA, Wirtz RM, Dafni U, Briasoulis E, et al. Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Br J Cancer. 2008; 99(11): 1775-85[DOI][PubMed]
  • 10. Koutras A, Kalogeras KT, Wirtz RM, Alexopoulou Z, Bobos M, Zagouri F, et al. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study. J Transl Med. 2015; 13: 171[DOI][PubMed]
  • 11. Bieche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer. 2003; 106(5): 758-65[DOI][PubMed]
  • 12. Lodge AJ, Anderson JJ, Gullick WJ, Haugk B, Leonard RC, Angus B. Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4. J Clin Pathol. 2003; 56(4): 300-4[DOI][PubMed]
  • 13. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2): 281-97[DOI][PubMed]
  • 14. Mesrian Tanha H, Mojtabavi Naeini M, Rahgozar S, Moafi A, Honardoost MA. Integrative computational in-depth analysis of dysregulated miRNA-mRNA interactions in drug-resistant pediatric acute lymphoblastic leukemia cells: an attempt to obtain new potential gene-miRNA pathways involved in response to treatment. Tumour Biol. 2016; 37(6): 7861-72[DOI][PubMed]
  • 15. Jin Y, Lee CG. Single Nucleotide Polymorphisms Associated with MicroRNA Regulation. Biomolecules. 2013; 3(2): 287-302[DOI][PubMed]
  • 16. Meshkat M, Tanha HM, Naeini MM, Ghaedi K, Sanati MH, Meshkat M, et al. Functional SNP in stem of mir-146a affects Her2 status and breast cancer survival. Cancer Biomark. 2016; 17(2): 213-22[DOI][PubMed]
  • 17. Bagheri F, Mesrian Tanha H, Mojtabavi Naeini M, Ghaedi K, Azadeh M. Tumor-promoting function of single nucleotide polymorphism rs1836724 (C3388T) alters multiple potential legitimate microRNA binding sites at the 3'-untranslated region of ErbB4 in breast cancer. Molecular Medicine Reports. 2016; 13: 4494-8[DOI]
  • 18. Gong J, Tong Y, Zhang HM, Wang K, Hu T, Shan G, et al. Genome-wide identification of SNPs in microRNA genes and the SNP effects on microRNA target binding and biogenesis. Hum Mutat. 2012; 33(1): 254-63[DOI][PubMed]
  • 19. Sasieni PD. From genotypes to genes: doubling the sample size. Biometrics. 1997; 53(4): 1253-61[PubMed]
  • 20. Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi OP, Elenius K. Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia. 2008; 13(2): 259-68[DOI][PubMed]
  • 21. Zhu XI, Song FJ, Zheng H, Zhang LN, Zhao YR, Chen KX. Relationship between polymorphism of ErbB4 gene in mirco-RNA binding site and the risk for breast cancer. Tumor. 2011; 31: 233-8
  • 22. Salimi Z, Sadeghi S, Tabatabaeian H, Ghaedi K, Fazilati M. rs11895168 C allele and the increased risk of breast cancer in Isfahan population. Breast. 2016; 28: 89-94[DOI][PubMed]
  • 23. Zabihi N, Sadeghi S, Tabatabaeian H, Ghaedi K, Azadeh M, Fazilati M. The association between rs1972820 and the risk of breast cancer in Isfahan population. J Cancer Ther Res.
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments